These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37220064)

  • 21. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Multistep Tumor Growth Model of High-Grade Serous Ovarian Carcinoma Identifies Hypoxia-Associated Signatures.
    More MH; Varankar SS; Naik RR; Dhake RD; Ray P; Bankar RM; Mali AM; Subbalakshmi AR; Chakraborty P; Jolly MK; Bapat SA
    Cells Tissues Organs; 2024; 213(2):79-95. PubMed ID: 35970135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
    Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
    Price JC; Azizi E; Naiche LA; Parvani JG; Shukla P; Kim S; Slack-Davis JK; Pe'er D; Kitajewski JK
    PLoS One; 2020; 15(6):e0233962. PubMed ID: 32525899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HNF-1β in ovarian carcinomas with serous and clear cell change.
    DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
    Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.
    Sato M; Sato S; Shintani D; Hanaoka M; Ogasawara A; Miwa M; Yabuno A; Kurosaki A; Yoshida H; Fujiwara K; Hasegawa K
    BMC Cancer; 2022 Jan; 22(1):59. PubMed ID: 35027024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
    Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
    Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole Reproductive System Non-Negative Matrix Factorization Mass Spectrometry Imaging of an Early-Stage Ovarian Cancer Mouse Model.
    Paine MR; Kim J; Bennett RV; Parry RM; Gaul DA; Wang MD; Matzuk MM; Fernández FM
    PLoS One; 2016; 11(5):e0154837. PubMed ID: 27159635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression.
    Quattrocchi L; Green AR; Martin S; Durrant L; Deen S
    Virchows Arch; 2011 Jul; 459(1):21-9. PubMed ID: 21509572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
    Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
    J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
    Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
    De Haven Brandon A; Box G; Hallsworth A; Court W; Matthews N; Herodek B; Arteagabeitia AB; Valenti M; Kirkin V
    Sci Rep; 2020 Jul; 10(1):10799. PubMed ID: 32612269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics.
    Konishi I; Abiko K; Hayashi T; Yamanoi K; Murakami R; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M;
    J Gynecol Oncol; 2022 Sep; 33(5):e83. PubMed ID: 36032027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
    Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
    [No Abstract]   [Full Text] [Related]  

  • 40. Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer.
    Vyhlídalová Kotrbová A; Gömöryová K; Mikulová A; Plešingerová H; Sladeček S; Kravec M; Hrachovinová Š; Potěšil D; Dunsmore G; Blériot C; Bied M; Kotouček J; Bednaříková M; Hausnerová J; Minář L; Crha I; Felsinger M; Zdráhal Z; Ginhoux F; Weinberger V; Bryja V; Pospíchalová V
    J Extracell Vesicles; 2024 Mar; 13(3):e12420. PubMed ID: 38490958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.